Business Wire

JAMESTOWN

24.2.2021 16:24:06 CET | Business Wire | Press release

Share
Jamestown Expands European Presence With More Than $1 Billion in Assets Under Management

Global real estate and investment company Jamestown today announced it has significantly expanded its global presence and now has more than $1 billion in European assets under management with the acquisition of another two buildings in Amsterdam, and a mandate to manage a portfolio of properties across Europe on behalf of one of its institutional investment partners and co-investors, E.ON Pension Trust. This latest news about its European portfolio comes on the heels of Jamestown’s recent purchase of three office buildings in Cologne, Germany, and just over a year after purchasing the iconic Groot Handelsgebouw in Rotterdam, one of the largest mixed-use buildings in the Netherlands, which currently houses more than 450 businesses.

“After entering the European market just over a year ago, Jamestown has grown its platform with $1 billion in assets under management and a knowledgeable real estate team headquartered in Cologne, Germany and offices in Amsterdam, London, and Madrid,” said Jamestown president Michael Phillips. “We continue to see many opportunities for future growth. Our vertically integrated team structure is at the root of our value-add asset management strategy enabling us to create innovative spaces while simultaneously preserving cities’ industrial pasts. As our European footprint expands, we will continue to focus on sustainable, adaptive reuse projects that bring new life to local communities.”

Jamestown’s newly acquired Dutch assets are in Amsterdam’s up-and-coming Schinkel neighborhood and include the historic A-Factorij, previously owned by E.ON Pension Trust and home to one of Jamestown’s European offices, and Helicopterstraat, a property previously owned by Gerose and comprised of four buildings on the adjoining Helicopterstraat, Vliegtuigstraat, and Valschermkade. The properties were acquired in partnership with E.ON Pension Trust and the RAG-Stiftung. E.ON Pension Trust made the decision to include A-Factorij in the co-investment given their belief in the long-term potential of the neighborhood, and that future opportunities in the neighborhood with the newly acquired properties are better acted on as co-investors.

In addition, Jamestown will provide asset management services for a portfolio of properties owned by E.ON Pension Trust in Italy, the Netherlands, Portugal, Spain, and the UK. The properties Jamestown will manage include a mix of shopping centers, office buildings, and mixed-use developments.

“We have known Jamestown for a long time and they have been a great partner to us in the US,” said Udo Schaffer, Vice President, Head of Real Estate, E.ON SE. “Jamestown is one of our preferred global partners given their active approach to asset management and focus on creative and out-of-the-box thinking. After several co-investments with Jamestown in Europe, we now look forward to working with them on the E.ON Pension Trust Separate Account Portfolio.”

A-Factorij (Pilotenstraat 35-45), a 128,177 square foot / 11,908 square meter former bicycle factory was originally built in 1955 and converted into a creative office space in 2002. Jamestown has been involved in management of the property since 2018. Adjacent to A-Factorij is Helicopterstraat, a 67,102 square foot / 6,234 square meter commercial property comprising four interconnected offices and industrial space, with a showroom and gym on the ground floor. The Schinkel district is transforming from industrial and loft offices to a true mixed-use community with a residential focus. The Amsterdam municipality plans to turn the 247-acre neighborhood into a vibrant, innovative, and sustainable district with international allure.

Gerose was represented by Appelhoven Real Estate Advisors in this off-market transaction.

Van Ooijen Accountants & Tax Advisors (Paul van der Aar and Adriaan Daniels) were the legal & tax advisors of the seller, together with HMK Notarissen. Greenberg Traurig represented Jamestown.

“This area of Amsterdam has generated a lot of interest from institutional and private investors from around the world,” said Stijn Uijthoven of Appelhoven Real Estate Advisors. “The properties Jamestown has acquired from Gerose Vastgoed were designed to be flexible and sustainable, and responsive to the changing neighborhood. It was a pleasure to work with Jamestown on this transaction and I look forward to seeing the evolution of the properties and the larger community in the coming years.”

Jamestown has a long-standing commitment to securing a better future for its tenants, residents, visitors, and investors by creating spaces that are sustainable, healthy, and inclusive. In 2020, after achieving its goal to reduce energy and greenhouse gas (GHG) emissions by 20 percent four years ahead of schedule, Jamestown committed to reducing its GHG emissions once again by committing to achieve net zero operational carbon by 2050. Jamestown also joined the ranks of other forward-thinking global organizations and 193 countries, and has adopted the United Nations Sustainable Development Goals into its corporate sustainability strategy.

For high-resolution images of A-Factorij and Helicopterstraat, please click here .

About Jamestown

Jamestown is a design-focused real estate investment and management company with a 37-year track record and a clear mission: to transform spaces into innovation hubs and community centers. Jamestown employs more than 400 people worldwide with headquarters in Atlanta, Georgia, and Cologne, Germany, and offices in Amsterdam, Bogotá, Boston, London, Los Angeles, Madrid, New York, and San Francisco. The company is well-known in the industry for its market discipline. Since its founding in 1983, Jamestown has executed transactions in excess of $35 billion, and as of December 31, 2020, the company has assets under management of $12.1 billion. Current and previous iconic projects include Chelsea Market in New York City, Industry City in Brooklyn, Ponce City Market in Atlanta, Ghirardelli Square in San Francisco, and the Innovation and Design Building in Boston. In addition to its portfolio in key markets throughout the U.S., Jamestown continues to expand its investment footprint to South America and Europe.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye